The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it ...

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical ...

An investigational intravesical drug-releasing system with erdafitinib is designed to provide prolonged release of ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...